CRISPR Therapeutics (NasdaqGM:CRSP) recently announced the departure of Chief Operating Officer Julianne Bruno, reflecting a notable leadership change that could influence its operational direction.

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...

CRISPR Therapeutics poised for growth with international potential and clinical assets. Read why I rate CRSP stock a Strong ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) was upgraded by StockNews.com to a “sell” rating in a report released on ...

Novo is paying up to $1 billion for a “non-incretin” medicine that might boost Wegovy’s effects. Elsewhere, Arbutus laid off ...

Crispr Therapeutics said Chief Operating Officer Julianne Bruno would depart the company to pursue other opportunities, effective April 11. Bruno joined the gene-editing company in 2019 and stepped ...

CRISPR Therapeutics’ Julianne Bruno is hitting the exit in favor of external opportunities, marking the latest shakeup to the ...

Crispr Therapeutics (CRSP) announced that its COO, Julianne Bruno, will be stepping down from the company to pursue external opportunities, ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases ...

Harbour Investments Inc. reduced its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 16.9% during the 4th ...

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...